Great progress has been made in many countries to tackle the HIV epidemic. A newly diagnosed patient with access to the latest antiretroviral therapy (ART) can hope to have a normal life expectancy. Yet, over 30 years since the emergence of the virus, and 28 years since the first World’s AIDS Day, much more needs to done to bring these advances to developing countries and to reach groups at high risk of HIV transmission. One of the biggest barriers to achieving this aim is the stigma that is still rife in many countries.
Seeking a cure for HIVSubscription
Efforts to find a cure for HIV were reinvigorated in 2008 when the case of Timothy Ray Brown showed that a cure is possible. Researchers and pharmaceutical companies are now seeking out the virus in its hiding places in an attempt to eradicate it completely.
Pharmacist Ana Martinez explains how involving pharmacists in HIV clinical trials earned her the highest honour from the International Pharmaceutical Federation.
The World Health Organization warns of increasing HIV drug resistance and issues new guidelines to address threatSubscription
Meg Caroline Doherty from the World Health Organization discusses the increasing number of cases HIV drug resistance, and the new guidelines and global action plan developed by the WHO to help countries address the threat.
HIV services need to evolve to meet new needsSubscription
A stronger, less fragmented system of HIV services is needed in order to keep pace with the changing needs of patients.
Limiting HIV resistance must not be neglected in an era where we continue to see breakthroughs in treatment for the infection once labelled a death sentence.
Unanswered questions about proposed PrEP trial Subscription
With 17 new HIV diagnoses made every day in the UK, we need to be bold and ambitious in our approach to HIV prevention — and this must include access to pre-exposure prophylaxis (PrEP) for all who need it.
NHS England has announced the start of the trial to provide pre-exposure prophylaxis (PrEP) to people at high risk of HIV infection in England, in order to gather clinical evidence on optimal targeting, uptake and implementation of PrEP on a large scale.
General practice-based HIV screening is an important public health intervention which should be used more widely, according to a study led by researchers at Queen Mary University of London and the London School of Hygiene and Tropical Medicine
REALITY trial, conducted by University College London, reduced death rates in HIV-infected adults and children by more than 25%.
A long-acting injectable antiretroviral therapy may be just as effective as a daily oral dose in treating HIV, a trial has shown.